YH 25448Alternative Names: YH25448
Latest Information Update: 15 Feb 2017
At a glance
- Originator Yuhan
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 07 Feb 2017 Yuhan Corporation plans a phase I trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease) in unspecified country (NCT03046992)
- 13 Jan 2016 Preclinical trials in Cancer in South Korea (unspecified route) before January 2016